脓毒症相关急性肾损伤:第28届急性疾病质量倡议工作组共识报告
该共识报告由第28届急性疾病质量倡议(ADQI)工作组制定,聚焦脓毒症相关急性肾损伤(SA-AKI)。SA-AKI定义为脓毒症起病7天内发生的AKI,分别按肾脏疾病改善全球结局(KDIGO)标准和Sepsis 3标准诊断。患者可表现为临床或亚临床AKI,早期识别有AKI风险或进展为严重和/或持续性AKI风险的患者,对及时启动充分支持措施(包括限制对肾脏的进一步打击)至关重要。尽管特异性治疗选择有限,已有临床试验评估集束化治疗和体外技术作为潜在治疗手段;共识提供分级推荐并指出未来研究重点。
要点
- SA-AKI定义为脓毒症起病7天内发生的AKI,诊断分别依据KDIGO标准与Sepsis 3标准。
- 患者可表现为临床或亚临床AKI,早期识别有AKI风险或进展为严重和/或持续性AKI风险者,对及时启动支持措施至关重要。
- 支持措施包括限制对肾脏的进一步打击;特异性治疗选择有限。
- 已有临床试验评估集束化治疗和体外技术作为潜在治疗手段。
- 共识提供SA-AKI管理的分级推荐,并指出未来研究重点。
适用人群与场景
- 重症患者中的脓毒症相关急性肾损伤(SA-AKI)患者。
诊断标准与关键阈值
- SA-AKI定义为脓毒症起病7天内发生的AKI,分别按肾脏疾病改善全球结局(KDIGO)标准和Sepsis 3标准诊断。
处置流程与药物剂量
- 及时启动充分的支持措施,包括限制对肾脏的进一步打击。
- 特异性治疗选择有限;已有临床试验评估集束化治疗和体外技术作为潜在治疗手段。
研究设计与关键结果
- 共识报告提供SA-AKI管理的分级推荐,并指出未来研究重点。
证据类型、等级与局限
- 证据类型:第28届急性疾病质量倡议(ADQI)工作组共识报告,提供分级推荐。
- 局限:原文未报告局限性
对床旁实践的改变
- 对脓毒症患者应在起病7天内按KDIGO标准评估AKI,并按Sepsis 3标准确认脓毒症,以识别SA-AKI。
- 应早期识别有AKI风险或进展为严重和/或持续性AKI风险的患者,及时启动充分支持措施,包括限制对肾脏的进一步打击。
- 特异性治疗选择有限;集束化治疗和体外技术作为潜在治疗手段已有临床试验评估。
指南或共识出处
- 第28届急性疾病质量倡议(ADQI)工作组共识报告《脓毒症相关急性肾损伤》,发表于Nat Rev Nephrol。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis-associated acute kidney injury (SA-AKI) is common in critically ill patients and is strongly associated with adverse outcomes, including an increased risk of chronic kidney disease, cardiovascular events and death. The pathophysiology of SA-AKI remains elusive, although microcirculatory dysfunction, cellular metabolic reprogramming and dysregulated inflammatory responses have been implicated in preclinical studies. SA-AKI is best defined as the occurrence of AKI within 7 days of sepsis onset (diagnosed according to Kidney Disease Improving Global Outcome criteria and Sepsis 3 criteria, respectively). Improving outcomes in SA-AKI is challenging, as patients can present with either clinical or subclinical AKI. Early identification of patients at risk of AKI, or at risk of progressing to severe and/or persistent AKI, is crucial to the timely initiation of adequate supportive measures, including limiting further insults to the kidney. Accordingly, the discovery of biomarkers associated with AKI that can aid in early diagnosis is an area of intensive investigation. Additionally, high-quality evidence on best-practice care of patients with AKI, sepsis and SA-AKI has continued to accrue. Although specific therapeutic options are limited, several clinical trials have evaluated the use of care bundles and extracorporeal techniques as potential therapeutic approaches. Here we provide graded recommendations for managing SA-AKI and highlight priorities for future research.
参考来源
- Zarbock A, Nadim MK, Pickkers P, et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023. PMID: 36823168. doi:10.1038/s41581-023-00683-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。